
TVRD Stock Forecast & Price Target
TVRD Analyst Ratings
Bulls say
Tvardi Therapeutics Inc's clinical candidate TTI-101 has demonstrated statistically significant improvements in fibrotic mediators and meaningful enhancements in lung function through favorable pharmacokinetic and pharmacodynamic data. The ongoing Phase 2 REVERT-IPF trial is expected to benefit from the robust pre-clinical results, indicating a positive outlook for TTI-101 in treating idiopathic pulmonary fibrosis (IPF). Additionally, the company's second product candidate, TTI-109, offers a significant advantage with approximately 80% bioavailability, enhancing the therapeutic potential for targeting STAT3 compared to both TTI-101 and existing therapies.
Bears say
Tvardi Therapeutics Inc. faces a negative outlook primarily due to concerns regarding the efficacy of its lead product candidate, TTI-101, in treating idiopathic pulmonary fibrosis (IPF). Clinical observations suggest that while TTI-101 has shown some mechanistic activity by reducing phosphorylated STAT3 levels, there is uncertainty about its therapeutic benefit, as the natural decline in forced vital capacity (FVC) among placebo patients may confound the expected outcomes. Additionally, discrepancies in baseline pulmonary function results and the inconsistent response of patients to TTI-101 highlight potential challenges in validating its success in clinical trials, raising further doubts about its commercial viability.
This aggregate rating is based on analysts' research of Cara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TVRD Analyst Forecast & Price Prediction
Start investing in TVRD
Order type
Buy in
Order amount
Est. shares
0 shares